• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

COA Responds to CMS Proposal to Ease Protections on 6 Drug Classes

Article

Community Oncology Alliance (COA) responded to CMS' proposal to ease restrictions on how Medicare Part D and Medicare Advantage plans dictate access to 6 protected drug classes, calling the decision a potential nightmare for vulnerable patients with cancer.

Community Oncology Alliance (COA) responded to CMS' proposal to ease restrictions on how Medicare Part D and Medicare Advantage plans dictate access to 6 protected drug classes, calling the decision a potential nightmare for vulnerable patients with cancer. According to COA, for the first time ever, Medicare patients with cancer and other serious diseases will no longer have guaranteed access to potentially life-saving drugs and instead will have to go through step therapy and formulary restrictions.

Noting their support of the administration's efforts to lower drug prices, COA argues that weakening or dismantling protected classes of drugs is too far. Read the full press release from Jeff Vacirca, MD, FACP, president of COA.

Related Videos
Dr Padma Sripada, Columbia Internal Medicine
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Joshua K. Sabari, MD< NYU Langone Perlmutter Cancer Center
dr marisa mcginley
Leslie Busby, MD, Rocky Mountain Cancer Centers
Camilla Levister
dr daniel ontaneda
Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.